JPH03504718A - 抗体活性及び広い作用スペクトルを有する調製物 - Google Patents

抗体活性及び広い作用スペクトルを有する調製物

Info

Publication number: JPH03504718A
Authority: JP; Japan
Prior art keywords: preparation according; preparation; colostrum; agent; treatment
Prior art date: 1988-04-19
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

JP1504068A

Other languages

English (en)

Japanese (ja)

Inventor

ディヒテルミューレル・ヘルベルト

シユテファン・ウオルフガング

リスネル・ラインハルト

アルント・リューディゲル

Original Assignee

ビオテスト・ファルマ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1988-04-19

Filing date

1989-04-18

Publication date

1991-10-17

1989-03-07 Priority claimed from EP89104016A external-priority patent/EP0338229B1/de

1989-04-18 Application filed by ビオテスト・ファルマ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング filed Critical ビオテスト・ファルマ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング

1991-10-17 Publication of JPH03504718A publication Critical patent/JPH03504718A/ja

Status Pending legal-status Critical Current

Links

238000002360 preparation method Methods 0.000 title claims description 90
230000000694 effects Effects 0.000 title claims description 24
230000009471 action Effects 0.000 title description 4
108060003951 Immunoglobulin Proteins 0.000 claims description 36
235000021277 colostrum Nutrition 0.000 claims description 36
210000003022 colostrum Anatomy 0.000 claims description 36
102000018358 immunoglobulin Human genes 0.000 claims description 36
239000003795 chemical substances by application Substances 0.000 claims description 28
238000000034 method Methods 0.000 claims description 19
206010012735 Diarrhoea Diseases 0.000 claims description 17
241000283690 Bos taurus Species 0.000 claims description 15
239000003814 drug Substances 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 10
239000000047 product Substances 0.000 claims description 9
230000006641 stabilisation Effects 0.000 claims description 9
238000011105 stabilization Methods 0.000 claims description 9
206010061598 Immunodeficiency Diseases 0.000 claims description 8
208000025865 Ulcer Diseases 0.000 claims description 8
208000025079 Yersinia infectious disease Diseases 0.000 claims description 8
231100000397 ulcer Toxicity 0.000 claims description 8
208000030507 AIDS Diseases 0.000 claims description 6
208000019637 Infantile Diarrhea Diseases 0.000 claims description 6
239000012141 concentrate Substances 0.000 claims description 6
201000006549 dyspepsia Diseases 0.000 claims description 6
241000124008 Mammalia Species 0.000 claims description 5
230000001154 acute effect Effects 0.000 claims description 5
OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 5
239000005018 casein Substances 0.000 claims description 5
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
235000021240 caseins Nutrition 0.000 claims description 5
208000029462 Immunodeficiency disease Diseases 0.000 claims description 4
206010022714 Intestinal ulcer Diseases 0.000 claims description 4
208000007107 Stomach Ulcer Diseases 0.000 claims description 4
230000001684 chronic effect Effects 0.000 claims description 4
239000012153 distilled water Substances 0.000 claims description 4
230000002496 gastric effect Effects 0.000 claims description 4
230000007813 immunodeficiency Effects 0.000 claims description 4
239000002244 precipitate Substances 0.000 claims description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
230000008029 eradication Effects 0.000 claims description 3
238000001990 intravenous administration Methods 0.000 claims description 3
238000010306 acid treatment Methods 0.000 claims description 2
230000002265 prevention Effects 0.000 claims description 2
210000000936 intestine Anatomy 0.000 claims 1
230000032696 parturition Effects 0.000 claims 1
239000003053 toxin Substances 0.000 description 26
231100000765 toxin Toxicity 0.000 description 26
108700012359 toxins Proteins 0.000 description 26
239000000243 solution Substances 0.000 description 19
235000013336 milk Nutrition 0.000 description 11
210000004080 milk Anatomy 0.000 description 11
239000008267 milk Substances 0.000 description 11
238000006386 neutralization reaction Methods 0.000 description 11
206010018910 Haemolysis Diseases 0.000 description 10
239000000427 antigen Substances 0.000 description 10
235000018102 proteins Nutrition 0.000 description 10
102000004169 proteins and genes Human genes 0.000 description 10
108090000623 proteins and genes Proteins 0.000 description 10
108091007433 antigens Proteins 0.000 description 9
102000036639 antigens Human genes 0.000 description 9
238000001694 spray drying Methods 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
230000002391 anti-complement effect Effects 0.000 description 8
108010008730 anticomplement Proteins 0.000 description 8
238000010790 dilution Methods 0.000 description 8
239000012895 dilution Substances 0.000 description 8
201000010099 disease Diseases 0.000 description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
238000001914 filtration Methods 0.000 description 8
230000008588 hemolysis Effects 0.000 description 8
239000006228 supernatant Substances 0.000 description 8
229940079593 drug Drugs 0.000 description 7
229940072221 immunoglobulins Drugs 0.000 description 7
239000000843 powder Substances 0.000 description 7
241001465754 Metazoa Species 0.000 description 6
238000006243 chemical reaction Methods 0.000 description 6
239000007788 liquid Substances 0.000 description 5
239000000725 suspension Substances 0.000 description 5
231100000699 Bacterial toxin Toxicity 0.000 description 4
241000191967 Staphylococcus aureus Species 0.000 description 4
239000000688 bacterial toxin Substances 0.000 description 4
239000002095 exotoxin Substances 0.000 description 4
231100000776 exotoxin Toxicity 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
239000000203 mixture Substances 0.000 description 4
OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
241000590002 Helicobacter pylori Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
239000005862 Whey Substances 0.000 description 3
102000007544 Whey Proteins Human genes 0.000 description 3
108010046377 Whey Proteins Proteins 0.000 description 3
206010048249 Yersinia infections Diseases 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
238000001514 detection method Methods 0.000 description 3
238000011026 diafiltration Methods 0.000 description 3
102000018146 globin Human genes 0.000 description 3
108060003196 globin Proteins 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000011146 sterile filtration Methods 0.000 description 3
208000035473 Communicable disease Diseases 0.000 description 2
241001522296 Erithacus rubecula Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108010040721 Flagellin Proteins 0.000 description 2
241000282412 Homo Species 0.000 description 2
108010046334 Urease Proteins 0.000 description 2
241000607734 Yersinia <bacteria> Species 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000003242 anti bacterial agent Substances 0.000 description 2
230000001147 anti-toxic effect Effects 0.000 description 2
229940088710 antibiotic agent Drugs 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000012510 hollow fiber Substances 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
208000026775 severe diarrhea Diseases 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000003860 storage Methods 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
235000009328 Amaranthus caudatus Nutrition 0.000 description 1
240000001592 Amaranthus caudatus Species 0.000 description 1
241000352320 Amegilla aeruginosa Species 0.000 description 1
241000589876 Campylobacter Species 0.000 description 1
241000205707 Cystoisospora belli Species 0.000 description 1
206010012742 Diarrhoea infectious Diseases 0.000 description 1
101500023984 Drosophila melanogaster Synapsin-1 Proteins 0.000 description 1
-1 ETEC Substances 0.000 description 1
241000257465 Echinoidea Species 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
206010015226 Erythema nodosum Diseases 0.000 description 1
208000007882 Gastritis Diseases 0.000 description 1
102000006395 Globulins Human genes 0.000 description 1
108010044091 Globulins Proteins 0.000 description 1
206010022678 Intestinal infections Diseases 0.000 description 1
206010023076 Isosporiasis Diseases 0.000 description 1
102000004407 Lactalbumin Human genes 0.000 description 1
108090000942 Lactalbumin Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000037581 Persistent Infection Diseases 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
102100031953 Protein 4.2 Human genes 0.000 description 1
101710196267 Protein 4.2 Proteins 0.000 description 1
206010037075 Protozoal infections Diseases 0.000 description 1
241000589517 Pseudomonas aeruginosa Species 0.000 description 1
108010017898 Shiga Toxins Proteins 0.000 description 1
241000256215 Spongomorpha aeruginosa Species 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
206010046851 Uveitis Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000002253 acid Substances 0.000 description 1
238000003916 acid precipitation Methods 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
201000009840 acute diarrhea Diseases 0.000 description 1
235000012735 amaranth Nutrition 0.000 description 1
239000004178 amaranth Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001142 anti-diarrhea Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
230000008901 benefit Effects 0.000 description 1
150000001621 bismuth Chemical class 0.000 description 1
OHJMTUPIZMNBFR-UHFFFAOYSA-N biuret Chemical compound NC(=O)NC(N)=O OHJMTUPIZMNBFR-UHFFFAOYSA-N 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
208000021735 chronic enteritis Diseases 0.000 description 1
239000011362 coarse particle Substances 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
235000013365 dairy product Nutrition 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000035622 drinking Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000000369 enteropathogenic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
238000003304 gavage Methods 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
238000009533 lab test Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
238000005461 lubrication Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000008569 process Effects 0.000 description 1
238000000746 purification Methods 0.000 description 1
230000000630 rising effect Effects 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
241000894007 species Species 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000024033 toxin binding Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Landscapes

Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Peptides Or Proteins (AREA)

JP1504068A 1988-04-19 1989-04-18 抗体活性及び広い作用スペクトルを有する調製物 Pending JPH03504718A (ja)

Applications Claiming Priority (8)

Application Number	Priority Date	Filing Date	Title
DE3813043		1988-04-19
DE3813043.2		1988-04-19
EP88118243.0		1988-11-02
EP88118243		1988-11-02
EP88121678		1988-12-24
EP88121678.2		1988-12-24
EP89104016A EP0338229B1 (de)	1988-04-19	1989-03-07	Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
EP89104016.4		1989-03-07

Publications (1)

Publication Number	Publication Date
JPH03504718A true JPH03504718A (ja)	1991-10-17

Family

ID=27434187

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP1504068A Pending JPH03504718A (ja)	1988-04-19	1989-04-18	抗体活性及び広い作用スペクトルを有する調製物

Country Status (9)

Country	Link
JP (1)	JPH03504718A (pt)
AT (1)	ATE90569T1 (pt)
AU (1)	AU637045B2 (pt)
BR (1)	BR8907385A (pt)
DK (1)	DK251990D0 (pt)
HU (1)	HU208089B (pt)
NO (1)	NO904440D0 (pt)
NZ (1)	NZ228595A (pt)
PT (1)	PT90318A (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE234855T1 (de) *	1993-09-20	2003-04-15	Anadis Ltd	Verfahren zur herstellung von immunoglobulinen aus colostrum und deren verwendung in pharmazeutischen zusammensetzungen
PL185442B1 (pl)	1996-10-03	2003-05-30	Georgiades Biotech Ltd	Środek farmaceutyczny o działaniu immunologicznym i psychotropowym, jego postać terapeutyczna oraz zastosowanie
NL1033696C2 (nl) *	2007-04-16	2008-10-20	Friesland Brands Bv	Aan melk ontleende antigeen-specifieke antilichamen, werkwijzen voor het bereiden en gebruik ervan.
WO2022148549A1 (en)	2020-01-14	2022-07-14	Babylat Gmbh	Apparatus and method for obtaining protein-enriched fractions from breast milk

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4051235A (en) *	1976-04-22	1977-09-27	Plymate Robert R	Method of preparing bovine colostrum for use in treating livestock
DE3432718C1 (de) *	1984-09-06	1986-05-22	Biotest Pharma GmbH, 6000 Frankfurt	Verfahren zur Herstellung einer Loesung von Milch- und/oder Kolostralimmunglobulinen

1989
- 1989-03-07 AT AT89104016T patent/ATE90569T1/de not_active IP Right Cessation
- 1989-04-04 NZ NZ228595A patent/NZ228595A/xx unknown
- 1989-04-18 AU AU34171/89A patent/AU637045B2/en not_active Expired - Fee Related
- 1989-04-18 HU HU892524A patent/HU208089B/hu not_active IP Right Cessation
- 1989-04-18 BR BR898907385A patent/BR8907385A/pt not_active Application Discontinuation
- 1989-04-18 JP JP1504068A patent/JPH03504718A/ja active Pending
- 1989-04-19 PT PT90318A patent/PT90318A/pt not_active Application Discontinuation
1990
- 1990-10-15 NO NO904440A patent/NO904440D0/no unknown
- 1990-10-18 DK DK251990A patent/DK251990D0/da not_active Application Discontinuation

Also Published As

Publication number	Publication date
DK251990A (da)	1990-10-18
NZ228595A (en)	1991-11-26
NO904440L (no)	1990-10-15
AU637045B2 (en)	1993-05-20
HU892524D0 (en)	1991-04-29
PT90318A (pt)	1989-11-10
AU3417189A (en)	1989-11-24
ATE90569T1 (de)	1993-07-15
BR8907385A (pt)	1991-05-21
NO904440D0 (no)	1990-10-15
DK251990D0 (da)	1990-10-18
HU208089B (en)	1993-08-30

Publication	Publication Date	Title
Rump et al.	1992	Treatment of diarrhoea in human immunodeficiency virus-infected patients with immunoglobulins from bovine colostrum
Mehra et al.	2006	Milk immunoglobulins for health promotion
EP0338229B1 (de)	1993-06-16	Präparat mit Antikörperaktivität und breitem Wirkungsspektrum, daraus bestehende oder diese enthaltende Mittel und deren Verwendung zur Behandlung von bakteriell oder toxin-bedingten Erkrankungen und zur Bekämpfung von Protozoen
US20050220894A1 (en)	2005-10-06	Colostrum-based composition
KR20000048855A (ko)	2000-07-25	닭의 난황 항체를 경구 투여하여 질병을 치료하는 방법
JP2002501526A (ja)	2002-01-15	乳汁における免疫グロブリンａの生成方法
NZ535195A (en)	2006-11-30	Compositions containing labile bioactive materials and mammalian colostrum, methods of preparation and treatment
EP0484148A1 (en)	1992-05-06	A method for producing a new medicine for both treating and preventing peptic ulcer diseases and gastritis and thus formulated medicines
CN106075436B (zh)	2020-01-03	一种不含抗生素的抗幽门螺杆菌口服制剂
US20220267419A1 (en)	2022-08-25	Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof
JPH03504718A (ja)	1991-10-17	抗体活性及び広い作用スペクトルを有する調製物
WO1999002188A1 (en)	1999-01-21	Hen egg yolk antibodies to clostridium difficile antigens and use in therapy for pseudomembranous colitis
JPH11512746A (ja)	1999-11-02	乳漿中の免疫グロブリンの単離方法
Jadhav et al.	2018	Antivenin production in India
AU696237B1 (en)	1998-09-03	Prevention and treatment of enterohemorrhagic E.Coli infection
ES2221705T3 (es)	2005-01-01	Utilizacion de anticuerpos aviares.
US5336490A (en)	1994-08-09	Haemophilus influenzae pilus vaccines
JPH04275232A (ja)	1992-09-30	胃炎，胃または十二指腸潰瘍予防食品
RU2264229C2 (ru)	2005-11-20	Препарат секреторного иммуноглобулина а, обладающий противовирусным и антибактериальным действием
CN114073765A (zh)	2022-02-22	一种抑制幽门螺杆菌的组合物及其应用
Selim et al.	2015	Development of IgY antibodies for control of tetanus
RU2453336C1 (ru)	2012-06-20	Средство, содержащее иммуноглобулины и обладающее антибактериальной и антивирусной активностью
RU2599029C1 (ru)	2016-10-10	Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
RU2647369C2 (ru)	2018-03-15	Способ лечения острой ожоговой токсемии организма и способ получения противоожоговой сыворотки реконвалесцентов для лечения ожоговой токсемии организма
DD283937A5 (de)	1990-10-31	Praeparat mit antikoerperaktivitaet und breitem wiekungsspektrum, daraus bestehende ode4 diese enthaltende mittel und deren verwendung zur behandlung von bakteriellen oder toxin-bedingten erkrankungen und zur bekaempfung von protozen